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Abstract. Uterine cervical cancer (UCC) is one of the main 
causes of cancer‑associated mortality in women. Inflamma-
tion has been identified as an important component of this 
neoplasia; in this context, anti‑inflammatory drugs represent 
possible prophylactic and/or therapeutic alternatives that 
require further investigation. Anti‑inflammatory drugs are 
common and each one may exhibit a different antineoplastic 
effect. As a result, the present study investigated different 
anti‑inflammatory models of UCC in vitro and in vivo. Cele-
coxib, sulindac, nimesulide, dexamethasone, meclofenamic 
acid, flufenamic acid and mefenamic acid were tested in UCC 
HeLa, VIPA, INBL and SiHa cell lines. The cytotoxicity of the 
drugs was evaluated in vitro. Celecoxib, sulindac, nimesulide, 
mefenamic acid and flufenamic acid presented with slight 
to moderate toxicity (10‑40% of cell death corresponding to 
100 µM) in certain cell lines, while meclofenamic acid exhib-
ited significant cytotoxicity in all essayed cell lines (50‑90% 
of cell death corresponding to 100 µM). The meclofenamic 
acid was tested in murine models (immunodeficient and 
immunocompetent) of UCC, which manifested a significant 
reduction in tumor growth and increased mouse survival. It was 
demonstrated that of the evaluated anti‑inflammatory drugs, 
meclofenamic acid was the most cytotoxic, with a significant 
antitumor effect in murine models. Subsequent studies are 
necessary to evaluate the clinical utility of this drug.
Introduction
Uterine cervical cancer (UCC) is one of the main causes of 
cancer-associated mortality in women. The main identi-
fied factor involved with disease development is chronic 
infection by high‑risk human papilloma virus (HPV) (1). 
Prevention by vaccination and premalignant lesion treatment 
are the best tools for decreasing the incidence of this condi-
tion. However, the diagnosis of UCC at the advanced stages 
is frequent in developing countries. In these conditions, the 
existing treatments are not effective and affect the quality of 
life; as a consequence, the requirement for novel treatments 
continues to be necessary. Inflammation has been identified as 
a critical component during tumor proliferation, progression 
and dissemination (2,3). Inflammation is induced and main-
tained mainly by the activity of the cyclooxygenase 2 (COX‑2) 
enzyme, and as a result, its inhibition may be adequately 
employed for cancer treatments. Among the pharmaceuti-
cals with high inhibition activity for COX‑2, non‑steroidal 
anti‑inflammatory drugs (NSAIDs) are considered to play a 
significant role (1,4‑6).
The chronic administration of different NSAIDs may 
contribute to reducing the incidence of diverse neoplasias (7) 
and these actions represent potential treatments. In this 
context, the fenamates, such as the meclofenamic acid, repre-
sent a group of the most potent NSAID COX‑2 inhibitors. 
Meclofenamic acid is a phenamate derivative that is not only 
a potent inhibitor of aldoketoreductases (AKRs) (8), enzymes 
that regulate the androgen, estrogen and progestin concentra-
tion, but also catalyzes the reduction of ketosteroids (9). The 
exerted inhibition of the NSAIDs over these enzymes has been 
considered as a proposed mechanism of the antineoplastic 
effect (10). Several anti‑inflammatories have also been probed 
experimentally as a UCC treatment, however, the obtained 
results were varied and it is difficult to establish the substance 
that has the greatest antineoplastic effect (11). In spite of the 
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fact that meclofenamic acid has previously been proposed as 
a promising antineoplastic drug, the fenamates have not yet 
been investigated in UCC. The aim of the present study was to 
evaluate the antineoplastic effect of several NSAIDs, including 
the fenamates, in in vitro and in vivo assays of UCC.
Materials and methods
Cell lines and drugs. The cell lines used in the present study, 
which were supplied by the Health Sciences Research and 
Development Center of Nuevo Leon Autonomous University 
(Monterrey, Mexico), were the human UCC HeLa, VIPA, 
INBL (HPV‑18+) and SiHa (HPV‑16+) cell lines, and the mouse 
TC‑1 (HPV‑16+) cell line (12,13), which were manipulated in a 
class II A2 laminar flow cabinet and maintained in Dulbecco's 
modified Eagle's medium (DMEM; Sigma‑Aldrich, St. Louis, 
MO, USA) supplemented with 10% (v/v) fetal bovine serum 
(FBS; Gibco Life Technologies, Carlsbad, CA, USA) at 37˚C, 
with 5% CO2 and 97% relative humidity (14,15). Celecoxib, 
sulindac, nimesulide, meclofenamic acid, flufenamic acid 
and mefenamic acid were obtained as powder salts with a 
pureness of 98% (Sigma‑Aldrich). The dexamethasone was 
acquired in solution for intravenous application (Chinoin 
Pharmaceutical Products, Aguascalientes, Mexico). Initially, 
the pharmaceutical salts were prepared in highly concentrated 
solutions. Celecoxib, sulindac and nimesulide were dissolved 
in dimethyl sulfoxide (Sigma‑Aldrich), while meclofenamic 
acid was dissolved in ethanol at 70%, mefenamic acid was 
dissolved in 0.1 M NaOH and flufenamic acid was dissolved in 
absolute ethanol (Sigma‑Aldrich).
Cytotoxicity assay (in vitro). The cells were plated in 96‑well 
plates (Corning Inc., Corning, NY, USA) at a density of 
1x103 cells per well, containing DMEM with 2% FBS. Subse-
quent to an initial 12‑h period, the cells were exposed to the 
different drugs (16) and incubated for 3 days. The cytotoxicity 
was determined with the Alamar Blue® reagent, according to 
the manufacturer's instructions (DIAsource ImmunoAssays, 
Nivelles, Belgium) (17). The cell viability was compared with 
untreated cells, which were considered to represent 100% 
viability. The assays were performed with two repetitions. 
In a first selection assay, celecoxib, sulindac, nimesulide, 
dexamethasone and meclofenamic acid were used in concen-
trations of 100 µM. In a subsequent assay, the fenamates, 
meclofenamic acid, flufenamic acid and mefenamic acid were 
used in concentrations of 0, 7.5, 15, 30, 60, 120 and 240 µM.
Murine model assays in UCC (in vivo). A total of 1x105 human 
HeLa [human papillomavirus (HPV)‑18+] cells were injected 
in the dorsal region of immunodeficient Foxn1(nu) female 
mice (nude), aged 4‑6 weeks (Harlan Mexico, Mexico City, 
Mexico). After 10‑15 days, when the tumors reached a length 
of 4 mm (small tumors), the mouse population was divided into 
two groups: Control group (treatment with saline solution) and 
experimental group (treatment with meclofenamic acid). The 
intraperitoneal drug application was performed over 30 days, 
at a dose of 10 mg/kg/day (tolerated dose in humans and mice) 
in a volume of 100 ml (16). The tumor was measured every 
5 days up to completion of the 30‑day treatment. In addition, a 
second assay was performed with two variations with respect 
to the previous experiments: i) A immunocompetent murine 
model was used; and ii) treatment was initiated when the 
tumors reached a larger size (a diameter of 10 mm). A total 
of 4x105 TC‑1 cells (HPV‑16+) were injected into the dorsal 
region of C57Bl/6 female mice (nude), aged 4‑6 weeks (Harlan 
Mexico, Mexico City, Mexico). After 20‑25 days, once the 
tumors had reached a diameter of 10 mm (large tumors), the 
mouse population was divided into a control group and an 
experimental group, to start the application of meclofenamic 
acid at the previously described dose for a period of 25 days, 
with measurements of the tumor every 3 days. The antitumor 
efficiency of meclofenamic acid was evaluated with the incre-
ment of the tumor volume and the survival curves. The tumor 
size was registered by measuring three dimensions (length, 
width and height) with a vernier gauge to compute the tumor 
volume, according to previously reported procedure (18). In 
consideration of the study protocols and ethics, the mice were 
sacrificed when the tumor reached 25 mm on any of its dimen-
sions, following the Mexican norms (NOM‑062‑ZOO‑1999) 
that regulate the use of laboratory animals (19,20). The study 
was approved by the ethics committee of the State Cancer 
Institute of Colima, Colima, Mexico (Certificate of Ethical 
Approval: REV1/ANTICEL/2013).
Statistical analysis. The cytotoxicity data in the cell lines 
were analyzed by descriptive statistics. The tumor growth was 
analyzed by statistical techniques for curves of tumor growth 
with no parametrical methods (free distribution) (19). Mouse 
survival was analyzed by Kaplan Meier curves, with the 
MedCalc statistical program, version 10 for Windows Vista 
(MedCalc Software, Ostend, Belgium). P<0.05 was used to 
indicate a statistically significant difference.
Results
Fig. 1A shows the viability of the different UCC cell lines 
exposed to different anti‑inflammatory drugs. Meclofenamic 
acid exhibited the highest cytotoxicity in the presence of the 
four tested cell lines. Celecoxib, sulindac and nimesulide also 
presented with partial cytotoxic activity, but only in certain cell 
lines. To evaluate if the meclofenamic acid effect was similar 
to the other drugs, a second assay was carried out employing 
multiple concentrations in the SiHa, HeLa and TC‑1 cell lines. 
Upon calculation of the necessary drug concentration lethal 
to 25% of cells (LC25) (Fig. 1B), it was observed that meclof-
enamic acid required a lower concentration to generate the 
same level of cell death. The LC50 could not be calculated, as 
only meclofenamic acid induced >50% cell death in all studied 
cell lines. This fact demonstrated that meclofenamic acid was 
the most cytotoxic drug among those studied, and the in vivo 
essays were consequently performed with this drug.
Two animal models with tumors associated with HPV 
were generated. The first model was immunodeficient with 
neoplasia of human HeLa HPV‑18+ cells, in which treatment 
was started when the tumors were small (4 mm diameter). 
A second model was immunocompetent with neoplasia of 
murine TC‑1 HPV‑16+ cells, in which treatment was started 
when the tumors were large (10 mm diameter). As shown in 
Fig. 2A, the small tumor model using HeLa cells displayed a 
clear reduction in tumor growth starting from day 10 of the 
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treatment period, and at the day 30, it was observed that the 
mice treated with meclofenamic acid presented with tumors 
that were 4-fold smaller in size than the control mice (admin-
istration with saline solution). The difference in the percentage 
tumor growth curve was statistically significant (P=0.0001). 
As shown in Fig. 2B, the tumor volume growth curve of the 
mice treated with meclofenamic acid was significantly lower 
than that of the control group (P=0.009). By contrast, in the 
large tumor model using TC‑1 cells, the neoplastic growth 
curve was performed until day 10. Although treatment was 
Figure 1. Percentage of cell viability after exposure of the 4 cell lines to 100 µM of different anti‑inflammatory drugs.  (A), evidencing that the meclofenamic 
acid is the most that occasions cytotoxicity. In the same way, the fig. depicts that from the fenamates; (B) the meclofenamic acid requires the lowest concentra-
tion to produce the 25% of cell death (LC25). Celecoxib, cele; sulindac, suli; dexamethasone, dexa; nimesulide, nime; meclofenamic acid, meclo.
Figure 2. Tumor growth in the (A) immunodeficient murine model that started treatment when tumors were small (4 mm diameter), and in the (B) immuno-
competent murine model that started treatment when the tumors were already large (10 mm diameter). In the two models, the administration of meclofenamic 
acid reduced the tumor growth.
Figure 3. Survival in two animal models with tumors associated with human papilloma virus. (A) A model was generated using HeLa cells in immunodeficient 
mice, (B) while a second model was generated with TC‑1 cells in immunocompetent mice. Mice treated with meclofenamic acid (10 mg/kg/day) survived for 
a longer period than those treated with saline solution (P=0.001 and P=0.038 for HeLa and TC‑1 models, respectively).
  A   B
  A   B
  A   B
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administered for 25 days, only 10 days of data are indicated 
in Fig. 2B, as 100% of the mice were alive during this period. 
Subsequently, mice began to die. It is noteworthy that although 
the differences are statistically significant, they are not as 
marked as those observed in the intitial animal model. It is 
noteworthy that although the differences are statistically 
significant, they are not as marked as those observed in the 
first animal model. In accordance with the previous results 
of the present study, the survival times of the mice treated 
with meclofenamic acid were significantly superior to the 
mice of the control group. The median survival times were 
100 vs. 52 days (treated vs. control) for the small tumor model 
using HeLa cells (Fig. 3A; P=0.001), and 29 vs. 19 days for the 
large tumor model using TC‑1 cells (Fig. 3B; P=0.038).
Discussion
Meclofenamic acid was revealed to be an efficient antineoplastic 
and antitumor agent in in vitro and in vivo models of UCC in the 
present study. Epidemiological studies have demonstrated that 
the chronic administration of several individually prescribed 
NSAIDs reduced the incidence of certain neoplasias (21,22). 
It has been postulated that the COX‑2 inhibition caused by 
NSAIDs generates anti‑proliferative and pro‑apoptotic effects 
in diverse cell lines, which could explain the therapeutic effects 
found in the present study. Nevertheless, there are few studies 
on the NSAID effects in UCC. Sulindac, aspirin, ibuprofen and 
celecoxib have exhibited apoptotic effects in UCC cell lines 
(in vitro) (23). In the present study, it was confirmed that the 
meclofenamic acid has a higher cytotoxic effect than sulindac 
or celecoxib. It is noteworthy that celecoxib, one of the most 
studied antineoplastic NSAIDs (16,24), did not exhibit an 
significant effect when compared with meclofenamic acid. This 
fact is in agreement with the poor benefits found in clinic assays 
where celecoxib was employed in UCC patients (25).
Notably, the drugs used in the present study (NSAIDs 
and dexamethasone) exhibited varied antineoplastic effects, 
which confirms that the inhibition of inflammation is not 
enough to generate an effect against cancer. The antitumor 
activity of meclofenamic acid was recently reported in pros-
tate cancer (11). It was proposed that the effect is not only 
caused by COX‑2 inhibition, but also by the strong inhibition 
of AKRs. Meclofenamic acid is one of the strongest NSAIDs 
in the inactivation of COX‑2, and it is also one of the most 
efficient to inactivate the AKRs. Therefore, all these observa-
tions have lead to the proposition that NSAIDs are a causative 
mechanism of antineoplastic effects (10).
In the in vitro and in vivo essays in the present study, 
the highest drug effect was observed in the HeLa (HPV‑18+) 
cells, which have a glandular origin (originally from cervix 
adenocarcinoma). This fact is in agreement with the suggested 
proposal that this meclofenamic acid may have stronger 
activity in neoplasias with a glandular origin (11). Nonethe-
less, the results of the present study showed the antineoplastic 
action in human cells of a squamous nature (SiHa, HPV‑16+). 
In addition, the same effectiveness was observed when the 
drug was applied to HPV‑16+ and HPV-18+ cells. The enhanced 
action of meclofenamic acid showed significant benefits as a 
cytotoxic‑effect drug in a model in which the treatment was 
started when the tumors were of a small size, as well as when 
mice with large tumors were treated. Although the best effect 
was evidently generated in the small tumor model of HeLa 
cells, the used models were not comparable; the immunode-
ficient and the immunocompetent models are characterized 
by tumor cells with different origins, since they precede from 
different mouse strains. However, these experiments confirm 
an antitumor effect even in the different studied models.
The dose employed in the animals, in accordance with 
previous results (11), did not have systemic toxic effects; 
in addition, it is notable that the immunodeficient model 
confirmed that the antitumor effect was caused directly by the 
drug action, without implicating the immune system.
In conclusion, the present study determined that meclof-
enamic acid is a potential antineoplastic agent against UCC 
or HPV‑dependent neoplasias. The clinical utility of the drug, 
possibly as a coadjuvant, requires further investigation in 
future clinical trials.
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